Eli Lilly
Indianapolis, IN – Shares of pharmaceutical giant Eli Lilly and Company (NYSE: LLY) experienced a dramatic decline today, plummeting by more than 14% in early trading, wiping out approximately $98 billion to $100 billion from its market capitalization. The significant sell-off was triggered by the release of disappointing clinical trial data
Eli Lilly
Indianapolis, IN – Shares of pharmaceutical giant Eli Lilly and Company (NYSE: LLY) experienced a significant downturn, plummeting over 10% in premarket trading and continuing to slide throughout the day, following the release of late-stage study results for its highly anticipated oral weight-loss drug, orforglipron. While the drug met its primary
Pfizer
Pfizer (NYSE: PFE), a name synonymous with pharmaceutical innovation and global health, stands as a testament to over 170 years of scientific endeavor and strategic evolution. What began as a modest chemical business in Brooklyn, New York, has transformed into one of the world's leading biopharmaceutical corporations, responsible
Avantor
Avantor (NYSE: AVTR) is a global leader in providing mission-critical products and services to customers in the life sciences and advanced technology industries. Headquartered in Radnor, Pennsylvania, the company plays a pivotal role in supporting scientific innovation across diverse sectors, from biopharmaceuticals and healthcare to education and government. Avantor'
Pfizer
Pfizer's (NYSE: PFE) next earnings call is anticipated to be around November 4, 2025, for the third quarter of 2025. This call is a crucial event for investors, analysts, and the public to gain insights into the pharmaceutical giant's financial performance, strategic direction, and future outlook.